Two Sigma Advisers LP Sells 72,100 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Two Sigma Advisers LP reduced its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 45.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 85,900 shares of the company's stock after selling 72,100 shares during the period. Two Sigma Advisers LP owned 0.20% of SI-BONE worth $1,204,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Rhumbline Advisers grew its stake in SI-BONE by 3.0% during the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company's stock worth $808,000 after buying an additional 1,683 shares during the period. MetLife Investment Management LLC boosted its position in SI-BONE by 17.6% during the 4th quarter. MetLife Investment Management LLC now owns 27,421 shares of the company's stock worth $384,000 after purchasing an additional 4,104 shares during the period. Proficio Capital Partners LLC acquired a new stake in SI-BONE in the 4th quarter valued at $155,000. Deutsche Bank AG raised its position in SI-BONE by 53.0% in the fourth quarter. Deutsche Bank AG now owns 36,268 shares of the company's stock valued at $508,000 after purchasing an additional 12,561 shares during the period. Finally, VELA Investment Management LLC raised its position in SI-BONE by 23.8% in the fourth quarter. VELA Investment Management LLC now owns 122,671 shares of the company's stock valued at $1,720,000 after purchasing an additional 23,592 shares during the period. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th. Truist Financial increased their target price on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Finally, Needham & Company LLC reissued a "buy" rating and set a $24.00 price target on shares of SI-BONE in a research report on Tuesday, May 6th.

Insider Activity

In other news, CFO Anshul Maheshwari sold 9,585 shares of SI-BONE stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $19.76, for a total value of $189,399.60. Following the completion of the sale, the chief financial officer now directly owns 224,507 shares in the company, valued at approximately $4,436,258.32. The trade was a 4.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Laura Francis sold 5,412 shares of the stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $19.49, for a total transaction of $105,479.88. Following the sale, the chief executive officer now owns 490,987 shares in the company, valued at $9,569,336.63. The trade was a 1.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 92,565 shares of company stock valued at $1,669,871 in the last 90 days. 4.00% of the stock is owned by company insiders.

SI-BONE Stock Down 2.2%

Shares of SI-BONE stock traded down $0.41 during trading on Wednesday, hitting $18.49. 343,602 shares of the stock traded hands, compared to its average volume of 378,235. The stock has a market cap of $787.95 million, a P/E ratio of -20.10 and a beta of 0.82. The company has a fifty day moving average price of $15.90 and a two-hundred day moving average price of $15.42. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $20.05. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25.

SI-BONE (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.09. The firm had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. Equities research analysts predict that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.